Strengthening Families & Communities LLC Has $148,000 Stock Holdings in Boston Scientific Corporation (NYSE:BSX)

Strengthening Families & Communities LLC boosted its position in Boston Scientific Corporation (NYSE:BSX) by 76.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,466 shares of the medical equipment provider’s stock after buying an additional 636 shares during the quarter. Strengthening Families & Communities LLC’s holdings in Boston Scientific were worth $148,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of BSX. Capital World Investors grew its stake in Boston Scientific by 28.7% in the fourth quarter. Capital World Investors now owns 27,899,903 shares of the medical equipment provider’s stock valued at $2,492,041,000 after purchasing an additional 6,216,199 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Boston Scientific by 11,720.3% during the 1st quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider’s stock worth $260,057,000 after acquiring an additional 2,556,078 shares during the last quarter. Northern Trust Corp boosted its stake in Boston Scientific by 18.0% in the 4th quarter. Northern Trust Corp now owns 14,595,627 shares of the medical equipment provider’s stock valued at $1,303,681,000 after purchasing an additional 2,221,790 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Boston Scientific by 18.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,839,362 shares of the medical equipment provider’s stock valued at $968,172,000 after purchasing an additional 1,709,461 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Boston Scientific by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock valued at $13,577,311,000 after purchasing an additional 1,697,945 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Trading Up 0.3%

Shares of Boston Scientific stock opened at $103.22 on Friday. Boston Scientific Corporation has a 52 week low of $75.00 and a 52 week high of $108.94. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.88 and a current ratio of 1.37. The stock has a 50 day moving average price of $103.54 and a two-hundred day moving average price of $102.07. The stock has a market capitalization of $152.95 billion, a PE ratio of 61.44, a price-to-earnings-growth ratio of 2.48 and a beta of 0.66.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%. The company’s revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter last year, the company earned $0.62 earnings per share. As a group, equities analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of the firm’s stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director directly owned 2,081 shares of the company’s stock, valued at $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 345,029 shares of company stock valued at $35,976,603 in the last ninety days. 0.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Citigroup reiterated a “buy” rating and set a $125.00 target price (up from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Needham & Company LLC restated a “buy” rating and set a $115.00 price objective on shares of Boston Scientific in a research report on Wednesday, May 28th. UBS Group upped their price objective on Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday, July 24th. Robert W. Baird upped their target price on Boston Scientific from $117.00 to $123.00 and gave the stock an “outperform” rating in a report on Thursday, July 24th. Finally, Truist Financial increased their price target on Boston Scientific from $120.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, July 24th. Two investment analysts have rated the stock with a hold rating, twenty-two have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $117.50.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.